RNA Delivery Function for Anticancer Therapeutics

This book presents an overview of the current status of translating the RNAi cancer therapeutics in the clinic, a brief description of the biological barriers in drug delivery, and the roles of imaging in aspects of administration route, systemic circulation, and cellular barriers for the clinical translation of RNAi cancer therapeutics, and with partial content for discussing the safety concerns. It then focuses on imaging-guided delivery of RNAi therapeutics in preclinical development, including the basic principles of different imaging modalities, and their advantages and limitations for biological imaging. With growing number of RNAi therapeutics entering the clinic, various imaging methods will play an important role in facilitating the translation of RNAi cancer therapeutics from bench to bedside. RNAi technique has become a powerful tool for basic research to selectively knock down gene expression in vitro and in vivo. Our scientific and industrial communities have started to develop RNAi therapeutics as the next class of drugs for treating a variety of genetic disorders, such as cancer and other diseases that are particularly hard to address with current treatment strategies.

Key Features

• Provides insight into the current advances and hurdles of RNAi therapeutics.
• Accelerates RNAi, miRNAs, and siRNA drug development for cancer therapy from bench to bedside.
• Addresses various modifications and novel delivery strategies for miRNAs, piRNAs and siRNA delivery in anticancer therapeutics.
• Explores the need for the interaction of hematologists,cell biologists, immunologists, and material scientists in the development of novel cancer therapies.
• Describes the current status of clinical trials related to miRNA and siRNA-based cancer therapy

• Presents remaining issues that need to be overcome to establish successful therapies.

Auteur

Prof. Loutfy H. Madkour is a professor of physical chemistry and nanoscience at Tanta University (Egypt). He received his BSc, MSc, and PhD in physical chemistry from the Cairo, Minia, and Tanta universities in Egypt, respectively. He has published 200 peer-reviewed original research articles, 20 review articles, and 8 books. He is an editorial board member of several international journals, including International Journal of Industrial Chemistry (IJIC-Springer), International Journal of Ground Sediment & Water, Global Drugs and Therapeutics, Chronicles of Pharmaceutical Science, Journal of Targeted Drug Delivery, UPI Journal of Pharmaceutical, Medical and Health Sciences, Global Journal of Nanomedicine, Clinical Pharmacology and Toxicology Research, Journal of Pharmacology & Pharmaceutical Research, LOJ Pharmacology & Clinical Research, CPQ Medicine, Pharmaceutical Sciences & Analytical Research Journal, Japan Journal of Research, Organic & Medicinal Chemistry International Journal, Nanotechnology & Applications, Materials Science Journal, Journal of Chemical Science and Chemical Engineering (Journals of- JCSCE), United Journal of Nanotechnology and Medicine, Clinical Practice (Therapy) journal, Journal of Materials New Horizons, Journal of Radiology and Medical Imaging. MedDocs Publishers, World Journal of Pharmacy and Pharmaceutical Sciences WJPPS and Journal of Material Science and Technology Research - RBM.

Contenu

Chapter 01

Cancer epigenetic mechanisms-DNA methylomes, histone codes and miRNAs Chapter 02

Circulating miRNAs cancer biomarkers and epigenetic modifications in human cancer Chapter 03

The role of circulating microRNAs in diagnosis, prognosis and treatment targets of cancer and diseases Chapter 04

MicroRNAs potential in human cancer as therapeutic targets and novel biomarkers Chapter 05

Biological function of miRNAs and piRNAs targets in cancer tissues Chapter 06

Delivery strategies for siRNA and modifications process of RNAi therapeutics for cancer treatment Chapter 07

Clinical small interfering siRNA-based conjugate systems for RNAi cancer cells therapy Chapter 08

Potential targeted for siRNA in types of genetic diseases cancer therapeutics Chapter 09

Recent advanced of microRNA molecules delivery as anticancer drugs Chapter 10

DNA damaging cancer therapies and FDA novel drug approvals Chapter 11

Therapeutic potential role of miRNAs in pancreatic and prostate cancer cells Chapter 12

Regulation of microRNAs and their role in regeneration and cancer diseases Chapter 13

Novel classes of non-coding RNAs (ncRNAs) and cancer biology therapeutic targets Chapter 14

Advances in the inhibition and optimization of checkpoint kinases by small molecules for the treatment of cancer Chapter 15

Recent therapeutic prospects of microRNAs and siRNA delivery systems in cancer treatment nano-biotechnology